180 Life (ATNF) Plunges 34%: A Biotech Meltdown Amid Sector Rotation and Technical Exhaustion

Summary
• 180 Life’s stock (ATNF) tumbles 34.07% intraday to $7.055, its lowest since 2025’s 52-week low of $0.66
• Intraday range spans $6.88 to $8.10 amid 25.01% turnover rate
• Sector peers like Amgen (AMGN) edge up 0.32% despite ATNF’s collapse

180 Life Sciences Corp. (ATNF) has experienced a catastrophic intraday selloff, with its stock price collapsing 34.07% to $7.055. The stock’s freefall has shattered key technical levels and triggered panic among traders, with RSI at 88.6 and MACD divergence signaling potential exhaustion. This sharp decline occurs amid a backdrop of sector rotation and profit-taking, as biotech investors shift capital toward more stable names like Amgen.

Sector Rotation and Profit-Taking Trigger Sharp Selloff
The collapse of 180 Life’s stock price appears driven by sector rotation and profit-taking rather than company-specific news. Despite a flurry of biotech advancements—from Scripps’ protein evolution tool to millipede-derived painkillers—investors have shifted capital toward more stable names like Amgen. ATNF’s lack of recent product milestones or clinical data contrasts with peers, making it vulnerable to broader market rotation. The stock’s 34.07% drop aligns with its 52-week low proximity ($0.66) and weak dynamic PE of -132.66, suggesting value investors have abandoned the name.

Biotech Sector Mixed as Amgen Gains Amid ATNF’s Collapse
While 180 Life’s stock plummets, sector leader Amgen (AMGN) gains 0.32% intraday, highlighting divergent performance within the biotech sector. ATNF’s collapse defies immediate sector logic, as biotech headlines buzz with breakthroughs in protein evolution and painkillers. The stock’s 34.07% drop—its worst single-day decline since 2020—has triggered panic among short-term traders, with RSI at 88.6 and MACD divergence signaling potential exhaustion.

Technical Divergence Signals Reversal: Key Levels to Watch
• MACD: 1.52 (above signal line 0.84), RSI: 88.6 (overbought), Bollinger Bands: Wide ($8.46 upper, $-1.11 lower)
• 200-day MA: $1.73 (far below current price), Support/Resistance: 30D ($0.798–$0.996), 200D ($0.891–$1.091)

ATNF’s technical profile screams exhaustion. The RSI at 88.6 and MACD histogram divergence suggest a bearish reversal is imminent. Immediate support lies at $6.88 (intraday low), with a breakdown below $6.88 triggering a test of the 52-week low. While no options are available for analysis, leveraged ETFs (unavailable in data) would typically be avoided here. Traders should monitor the 30-day support range ($0.798–$0.996) for potential short-term bounces. Aggressive bears may consider shorting into a rebound above $7.20, but the lack of liquidity in options makes this high-risk.

Backtest 180 Life Stock Performance
The backtest of ATNF's performance after an intraday plunge of -34% shows mixed results. While the 3-Day win rate is relatively high at 41.09%, the 10-Day and 30-Day win rates are lower at 35.47% and 36.56%, respectively. This suggests that while ATNF may bounce back in the short term, longer-term returns are more volatile. The maximum return during the backtest period was -0.91%, indicating that even in the best-case scenario, ATNF would not recover its pre-plunge levels for several days.

Act Now: Target $6.88 Support or Exit Long Positions
180 Life’s freefall shows no immediate signs of abating, with technical indicators and sector rotation pointing to continued weakness. The stock’s proximity to its 52-week low and negative PE ratio make it a high-risk proposition. Investors should prioritize exiting long positions or shorting into any rebounds above $7.20. Meanwhile, sector leader Amgen’s 0.32% gain highlights the biotech sector’s relative stability. Watch for a breakdown below $6.88 to confirm the bearish thesis—this could trigger a cascade toward $0.66. For now, the message is clear: ATNF is a sell, not a hold.